Cat. No. | Product name | CAS No. |
DCAPI1419 |
Losartan
Losartan is a potent, non peptide antagonist of the angiotensin II receptor type 1. This receptor initiates a signal cascade that causes vasoconstriction. Antagonism of this receptor in turn causes vasodilation by blocking the signal from angiotensin II. |
114798-26-4 |
DC9153 |
Losartan Potassium
Featured
Losartan is an angiotensin II receptor antagonist, competes with the binding of angiotensin II to AT1 receptors with IC50 of 20 nM. |
124750-99-8 |
DC7711 |
Losmapimod
Featured
Losmapimod (GW856553X) is a selective, potent, and orally active p38 MAPK inhibitor with pKi of 8.1 and 7.6 for p38α and p38β, respectively. Phase 3. |
585543-15-3 |
DCAPI1355 |
Loteprednol etabonate
Loteprednol etabonate |
82034-46-6 |
DC9837 |
Larotrectinib (LOXO-101 sulfate)
Featured
LOXO-101 is a small molecule that was designed to block the ATP binding site of the TRK family of receptors, with 2 to 20 nM cellular potency against the TRKA, TRKB, and TRKC kinases. |
1223405-08-0 |
DC11448 |
LOXO 195(Selitrectinib)
Featured
LOXO-195 is a next-generation TRK kinase (TKI) inhibitor, with IC50s of 0.6±0.1 nM, <2.5 nM for TRKA and TRKC respectively. |
2097002-61-2 |
DC8541 |
ORY-1001(Ladademstat)
Featured
ORY-1001 dihydrochloride (RG-6016, Ladademstat) is a highly potent, selective inhibitor of lysine-specific demethylase KDM1A (LSD1) with IC50 of 18 nM, displays high selectivity for KDM1A over other FAD-containing monoamine oxidases. |
1431303-72-8 |
DC10755 |
LSZ-102
Featured
LSZ102 is a potent, orally bioavailable Selective Estrogen Receptor Degrader (SERD) for the Treatment of Estrogen Receptor Positive Breast Cancer. |
2135600-76-7 |
DC10987 |
LTX-315
This product is discontinued. LTX-315 (Oncopore) is a synthetic 9-mer anticancer peptide that preferentially permeabilizes mitochondrial membranes, thereby causing partially BAX/BAK1-regulated, caspase-independent necrosis. |
1345407-05-7 |
DC11422 |
Lumateperone Tosylate
Featured
Lumateperone Tosylate is a 5-HT2A receptor antagonist (Ki = 0.54 nM), a partial agonist of presynaptic D2 receptors and an antagonist of postsynaptic D2 receptors (Ki = 32 nM), and a SERT blocker (Ki = 61 nM). |
1187020-80-9 |
DC9938 |
Lusutrombopag(S-888711)
Featured
Lusutrombopag(S-888711) is an orally bioavailable, small molecule thrombopoietin (TPO) receptor agonist being developed by Shionogi for chronic liver disease (CLD) patients with thrombocytopenia prior to elective invasive surgery. |
1110766-97-6 |
DC7456 |
LX1606 Hippurate
Featured
LX1606 is an orally bioavailable, small-molecule, tryptophan hydroxylase (TPH) inhibitor with potential antiserotonergic activity. |
1137608-69-5 |
DC10765 |
LX-2761
LX2761 is a locally acting SGLT1 inhibitor that is highly potent in vitro and delays intestinal glucose absorption in vivo to improve glycemic control. |
1610954-97-6 |
DC7921 |
Sotagliflozin (LX-4211)
Featured
LX-4211 is a potent dual SGLT2/1 inhibitor; Antidiabetic agents. |
1018899-04-1 |
DC10828 |
LXH254
Featured
LXH254 is a potent CRAF inhibitor extracted from patent WO2018051306A1, Compound A. LXH254 also is a potent BRAF inhibitor. |
1800398-38-2 |
DC2072 |
LXR623
Featured
LXR-623 is a novel Liver X Receptor modulator |
875787-07-8 |
DC6306 |
LY2157299(Galunisertib)
Featured
LY2157299 is a potent TGFβ receptor I (TβRI) inhibitor with IC50 of 56 nM. Phase 2. |
700874-72-2 |
DC8630 |
Ralimetinib 2MsOH(LY2228820)
Featured
LY2228820 is a novel and potent p38MAPK inhibitor (the IC50 for p38αMAPK and p38βMAPK were 7 nM and 3 nM, respectively). |
862507-23-1 |
DC10782 |
LY2510924
Featured
LY2510924 is an inhibitor of CXC chemokine receptor 4 (CXCR4), with potential antineoplastic activity. |
1088715-84-7 |
DC7943 |
LYS6K2(LY2584702) tosylate salt
Featured
LY-2584702 is an orally available inhibitor of p70S6K signaling; inhibits p70S6K and prevents phosphorylation of the S6 subunit of ribosomes. |
1082949-68-5 |
DC7103 |
LY2603618(IC-83)
Featured
LY2603618(IC-83) is a potent and selective small molecule inhibitor of Chk1 protein kinase activity in vitro (IC50=7 nM) and the first selective Chk1 inhibitor to enter clinical cancer trials. |
911222-45-2 |
DC7993 |
Prexasertib (LY2606368) 2HCl
Featured
LY2606368 2Hcl is a potent and selective ATP competitive inhibitor(IC50=1.5 nM in SW1990 cell) of the Chk1 protein kinase. |
1234015-54-3 |